We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Plasma Levels of Matrix Metalloproteinases (MMPs) and Degree of DNA Fragmentation in Pseudoexfoliation (PEX) Glaucoma

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00327613
First Posted: May 18, 2006
Last Update Posted: September 26, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
University Hospital, Basel, Switzerland
  Purpose

Glaucoma is a worldwide leading cause of blindness. The key feature of this ocular neuropathy is characterized by an excavating optic nerve head. Loss of retinal ganglion cells is the final end point in blinding diseases of the optic nerve such as glaucoma. It is known that neuronal cell death in glaucoma occurs by apoptotic mechanism. In earlier studies, the investigators demonstrated that the process of apoptosis is reflected in circulating leukocytes by different parameters, like differential messenger ribonucleic acid (mRNA) expression and an increased fragmentation of the deoxyribonucleic acid (DNA). Such alterations point out a relationship between cellular stress and apoptotic events.

Based on the results of mRNA-expression, the investigators also expect alterations on the protein level.

This study is, therefore, designed to characterize the proteome related to the proteins involved in cell death related pathways.

Thus the expression pattern of several proteins in leukocytes from patients with primary open angle glaucoma will be analyzed by techniques like Western-blot and tandem mass spectrometry. These samples will be compared with healthy controls. In addition, they will be also compared with samples from patients with Parkinson's disease. Since glaucoma is a neurodegenerative disease, these patients will be included as a positive control in this study.


Condition
Pseudoexfoliation Syndrome Glaucoma

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Plasma Levels of Matrix Metalloproteinases and Degree of DNA Fragmentation in Patients With Pseudoexfoliation Syndrome and Open-Angle Glaucoma (PEXG)

Resource links provided by NLM:


Further study details as provided by University Hospital, Basel, Switzerland:

Enrollment: 60
Study Start Date: June 2005
Study Completion Date: April 2008
Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)
  Show Detailed Description

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with pseudoexfoliation
Criteria

Inclusion Criteria:

  • German native speakers
  • Age between 18-80 years
  • Pseudoexfoliation syndrome
  • Pseudoexfoliation syndrome with open-angle glaucoma
  • Primary open-angle glaucoma

Exclusion Criteria:

  • Any history of ocular or systemic diseases other than glaucoma or of drug or alcohol abuse.
  • Any condition potentially interfering with the visual field results. Visual fields will be obtained from the chart.
  • Any mentally impaired patient.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00327613


Locations
Switzerland
University Eye Clinic Basel
Basel, BS, Switzerland, 4031
Sponsors and Collaborators
University Hospital, Basel, Switzerland
Investigators
Study Director: Selim Orgül, MD University Hospital, Basel, Switzerland
  More Information

Responsible Party: Selim Orgul, University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier: NCT00327613     History of Changes
Other Study ID Numbers: 066-WUK-2005-001
First Submitted: May 17, 2006
First Posted: May 18, 2006
Last Update Posted: September 26, 2008
Last Verified: September 2008

Keywords provided by University Hospital, Basel, Switzerland:
PEX
glaucoma
MMP
DNA degradation
POAG
Healthy subjects

Additional relevant MeSH terms:
Syndrome
Glaucoma
Exfoliation Syndrome
Disease
Pathologic Processes
Ocular Hypertension
Eye Diseases
Iris Diseases
Uveal Diseases